Fluoxetine and all other SSRIs are 5-HT2B agonists - Importance for their therapeutic effects

Current Neuropharmacology

Volumn 12, Issue 4, 2014, Pages 365-379

  Peng, Liang ^a   Gu, Li ^a   Li, Baoman ^a   Hertz, Leif ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

5 HT2A receptor; 5 HT2B receptor; Astrocytes; Gene expression; SSRIs

Indexed keywords

CARBAMAZEPINE; FLUOXETINE; SEROTONIN 2B RECEPTOR; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

ARTICLE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GLUCOSE METABOLISM; GLYCOGENOLYSIS; HIPPOCAMPUS; HUMAN; INFLAMMATION; MAJOR DEPRESSION; NONHUMAN; PHOSPHORYLATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

EID: 84911477828     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X12666140828221720     Document Type: Article

References (117)

1. Wong, D. T.; Perry, K. W.; Bymaster, F. P. Case history: the discovery of fluoxetine hydrochloride (Prozac). Nat. Rev. Drug Discov., 2005, 4, 764-774. DOI: 10. 1016/j. ajo. 2005. 02. 011.
2. Fuller, R. W.; Wong, D. T. Inhibition of serotonin reuptake. Fed. Proc., 1977, 36, 2154-2158. PubMed ID: 326579.
3. Wong, D. T.; Bymaster, F. P.; Reid, L. R.; Threlkeld, P. G. Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem. Pharmacol., 1983, 32, 1287-1293. DOI: 10. 1016/0006-2952(83)90284-8.
4. Wong, D. T.; Bymaster, F. P. Development of antidepressant drugs. Fluoxetine (Prozac) and other selective serotonin uptake inhibitors. Adv. Exp. Med. Biol., 1995, 363, 77-95. PubMed ID: 7618533.
5. Foguet, M.; Nguyen, H.; Le, H.; Lübbert, H. Structure of the mouse 5-HT1C, 5-HT2 and stomach fundus serotonin receptor genes. Neuroreport, 1992, 3, 345-348. http://dx. doi. org/10. 1097/00001756- 199204000-00014.
6. Schmuck, K.; Ullmer, C.; Engels, P.; Lübbert, H. Cloning and functional characterization of the human 5-HT2B serotonin receptor. FEBS Lett., 1994, 342, 85-90. http://dx. doi. org/10. 1016/0014- 5793(94)80590-3.
7. Hertz, L.; Baldwin, F.; Schousboe, A. Serotonin receptors on astrocytes in primary cultures: effects of methysergide and fluoxetine. Can. J. Physiol Pharmacol., 1979, 57, 223-226. http://dx. doi. org/10. 1139/y79-034.
8. Kong, E. K.; Peng, L.; Chen, Y.; Yu, A. CH; Hertz, L. Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration. Neurochem. Res., 2002, 27, 113-120. http://dx. doi. org/10. 1023/ai 1014862808126.
9. Chen, Y.; Peng, L.; Zhang, X.; Stolzenburg, J. U.; Hertz, L. Further evidence that fluoxetine interacts with a 5-HT2C receptor in glial cells. Brain Res. Bull., 1995, 38, 153-159. http://dx. doi. org/ 10. 1016/0361-9230(95)00082-p.
10. Hertz, L.; Li, B.; Song, D.; Ren, J.; Dong, L.; Chen, Y.; Peng, L. Astrocytes as a 5-HT2B-mediated, SERT-independent SSRI target, slowly altering depression-associated genes and functions. Curr. Signal. Transduct. Ther., 2012, 7, 65-80. http://dx. doi. org/10. 2174/ 1574362799278154.
11. Zhang, S.; Li, B.; Lovatt, D.; Xu, J.; Song, D.; Goldman, S. A.; Nedergaard, M.; Hertz, L.; Peng, L. 5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional 'serotonin-specific reuptake inhibitors'. Neuron Glia. Biol., 2010, 6, 113-125. http://dx. doi. org/10. 1017/s1740925x 10000141.
12. Diaz, S. L.; Doly, S.; Narboux-Nême, N.; Fernández, S.; Mazot, P.; Banas, S. M.; Boutourlinsky, K.; Moutkine, I.; Belmer, A.; Roumier, A.; Maroteaux, L. 5-HT(2B) receptors are required for serotonin-selective antidepressant actions. Mol. Psychiatry, 2012, 17, 154-163. http://dx. doi. org/10. 1038/mp. 2011. 159.
13. Manev, H.; Uz, T.; Manev, R. Glia as a putative target for antidepressant treatments. J. Affect Disord., 2003, 75, 59-64. http://dx. doi. org/10. 1016/s0165-0327(02)00044-7.
14. Launay, J. M.; Schneider, B.; Loric, S.; Da Prada, M.; Kellermann, O. Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells. FASEB J. 2006, 20, 1843-1854. http://dx. doi. org/10. 1096/fj. 06-5724com.
15. Sun, W.; McConnell, E.; Pare, J. F.; Xu, Q.; Chen, M.; Peng, W.; Lovatt, D.; Han, X.; Smith, Y.; Nedergaard, M. Glutamate-dependent neuroglial calcium signaling differs between young and adult brain. Science, 2013, 339, 197-200. http://dx. doi. org/10. 1126/ science. 1226740.
16. Hertz, L. The Glutamate-Glutamine (GABA) Cycle: Importance of Late Postnatal Development and Potential Reciprocal Interactions between Biosynthesis and Degradation. Front. Endocrinol (Lausanne), 2013a, 4, 59. http://dx. doi. org/10. 3389/fendo. 2013. 00059.
17. Sarkar, A.; Chachra, P.; Vaidya, V. A. Postnatal Fluoxetine-Evoked Anxiety Is Prevented by Concomitant 5-HT(2A/C) Receptor Blockade and Mimicked by Postnatal 5-HT(2A/C) Receptor Stimulation. Biol. Psychiatry, 2014, in press.
18. Bengel, D.; Murphy, D. L.; Andrews, A. M.; Wichems, C. H.; Feltner, D.; Heils, A.; Mössner, R.; Westphal, H.; Lesch, K. P. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol. Pharmacol., 1998, 53, 649-655. PMID 9547354.
19. Choi, D. S.; Maroteaux, L. Immunohistochemical localisation of the serotonin 5-HT2B receptor in mouse gut, cardiovascular system, and brain. FEBS Lett, 1996, 391, 45-51. http://dx. doi. org/10. 1016/0014- 5793(96)00695-3.
20. Li, B.; Dong, L.; Wang, B.; Cai, L.; Jiang, N.; Peng, L. Cell type-specific gene expression and editing responses to chronic fluoxetine treatment in the in vivo mouse brain and their relevance for stress-induced anhedonia. Neurochem. Res., 2012, 37, 2480-2495. http://dx. doi. org/10. 1007/s11064-012-0814-1.
21. Blier, P.; De Montigny, C. Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat. J. Neurosci., 1983, 3, 1270-1278. PubMed ID: 6304261.
22. McDevitt, R. A.; Neumaier, J. F. Regulation of dorsal raphe nucleus function by serotonin autoreceptors: a behavioral perspective. J. Chem. Neuroanat., 2011, 41, 234-246. http://dx. doi. org/10. 1016/ j. jchemneu. 2011. 05. 001.
23. Czachura, J. F.; Rasmussen, K. Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat. Naunyn Schmiedebergs Arch. Pharmacol., 2000, 362, 266-275. http://dx. doi. org/10. 1007/ s002100000290.
24. Descarries, L.; Riad, M. Effects of the antidepressant fluoxetine on the subcellular localization of 5-HT1A receptors and SERT. Philos. Trans. R Soc. Lond. B Biol Sci., 2012, 367, 2416-2425. http://dx. doi. org/10. 1098/rstb. 2011. 0361.
25. Miguelez, C.; Grandoso, L.; Ugedo, L. Locus coeruleus and dorsal raphe neuron activity and response to acute antidepressant administration in a rat model of Parkinson's disease. Int. J. Neuro-psychopharmacol., 2011, 14, 187-200. http://dx. doi. org/10. 1017/ s146114571000043x.
26. Artigas, F.; Romero, L.; de Montigny, C.; Blier, P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci., 1996, 19, 378-383. http://dx. doi. org/10. 1016/s0166-2236(96)10037-0.
27. Berman, R. M.; Anand, A.; Cappiello, A.; Miller, H. L., Hu, X. S., Oren, D. A., Charney, D. S. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol. Psychiatry, 1999, 45, 1170-1177. http://dx. doi. org/10. 1016/s0006-3223(98)00383-7.
28. Önder, E.; Tural, U. Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone. J. Affect Disord., 2003, 76, 223-227. http://dx. doi. org/10. 1016/s0165-0327 (02)00090-3.
29. Li, B.; Zhang, S.; Zhang, H.; Nu, W.; Cai, L.; Hertz, L.; Peng, L. Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation. Psychopharmacology (Berl), 2008, 201, 443-458. http://dx. doi. org/ 10. 1007/s00213-008-1306-5.
30. Zhang, X.; Peng, L.; Chen, Y.; Hertz, L. Stimulation of glycogenolysis in astrocytes by fluoxetine, an antidepressant acting like 5-HT. Neuroreport, 1993, 4, 1235-1238. http://dx. doi. org/ 10. 1097/00001756-199309000-00006.
31. Gibbs, M. E.; Hutchinson, D.; Hertz, L. Astrocytic involvement in learning and memory consolidation. Neurosci. Biobehav. Rev., 2008, 32, 927-944. http://dx. doi. org/10. 1016/j. neubiorev. 2008. 02. 001.
32. Gibbs, M. E.; Hertz, L. Serotonin mediation of early memory formation via 5-HT2B receptor-iduced glycogenolysis in the day-old chick. Front. Pharmacol., 2014, 5, 54. http://dx. doi. org/10. 3389/ fphar. 2014. 00054.
33. Li, X.; Zhu, W.; Roh, M. S.; Friedman, A. B.; Rosborough, K.; Jope, R. S. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology, 2004, 29, 1426-1431. http://dx. doi. org/10. 1038/ sj. npp. 1300439.
34. Polter, A. M.; Yang, S.; Jope, R. S.; Li, X. Functional significance of glycogen synthase kinase-3 regulation by serotonin. Cell Signal., 2012, 24, 265-271. http://dx. doi. org/10. 1016Zj. cellsig. 2011. 09. 009.
35. Price, R. D.; Weiner, D. M.; Chang, M. S.; Sanders-Bush, E. RNA editing of the human serotonin 5-HT2C receptor alters receptor-mediated activation of G13 protein. J. Biol. Chem., 2001, 276, 44663-44668. http://dx. doi. org/10. 1074/jbc. m106745200.
36. Hertz, L.; Song, D.; Li, B.; Du, T.; Xu, J.; Gu, L.; Chen, Y.; Peng, L. Signal transduction in astrocytes during chronic or acute treatment with drugs (SSRIs; anti-bipolar drugs; GABA-ergic drugs; benzodiazepines) ameliorating mood disorders. J. Signal. Transduc., 2014, 2014, 593934.
37. Sawyer, E. K.; Howell, L. L. Pharmacokinetics of fluoxetine in rhesus macaques following multiple routes of administration. Pharmacology, 2011, 88, 44-49. http://dx. doi. org/10. 1159/ 000329417.
38. Li, B.; Gu, L.; Hertz, L.; Peng, L. Expression of nucleoside transporter in freshly isolated neurons and astrocytes from mouse brain. Neurochem. Res., 2013, 38, 2351-2358. http://dx. doi. org/ 10. 1007/s11064-013-1146-5.
39. Eriksen, J. L.; Gillespie, R.; Druse, M. J. Effects of ethanol and 5-HT1A agonists on astroglial S100B. Brain Res. Dev. Brain Res., 2001, 139, 97-105. http://dx. doi. org/10. 1016/s0165-3806(02) 00510-2.
40. Miyazaki, I.; Asanuma, M.; Murakami, S.; Takeshima, M.; Torigoe, N.; Kitamura, Y.; Miyoshi, K. Targeting 5-HT(1A) receptors in astrocytes to protect dopaminergic neurons in Parkinsonian models. Neurobiol. Dis., 2013, 59, 244-256. http://dx. doi. org/10. 1016/j. nbd. 2013. 08. 003.
41. Li, B.; Zhang, S.; Li, M.; Hertz, L.; Peng, L. Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2B-induced, transactivation-mediated ERK1/2 phosphorylation. Psychopharmacology (Berl), 2009, 207, 1-12. http://dx. doi. org/10. 1007/ s00213-009-1631-3.
42. Bass, B. L. RNA editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem., 2002, 71, 817-846. http://dx. doi. org/ 10. 1146/annurev. biochem. 71. 110601. 135501.
43. Valente, L.; Nishikura, K. ADAR gene family and A-to-I RNA editing: diverse roles in posttranscriptional gene regulation. Prog. Nucleic Acid Res. Mol Biol, 2005, 79, 299-338. http://dx. doi. org/ 10. 1016/s0079-6603(04)79006-6.
44. Kawahara, Y.; Ito, K.; Sun, H.; Ito, M.; Kanazawa, I.; Kwak, S. Regulation of glutamate receptor RNA editing and ADAR mRNA expression in developing human normal and Down's syndrome brains. Brain Res. Dev. Brain Res., 2004, 148, 151-155. http://dx. doi. org/10. 1016/j. devbrainres. 2003. 11. 008.
45. Köhr, G.; Melcher, T.; Seeburg, P. H. Candidate editases for GluR channels in single neurons of rat hippocampus and cerebellum. Neuropharmacology, 1998, 37, 1411-1477. http://dx. doi. org/ 10. 1016/s0028-3908(98)00149-x.
46. Li, B.; Zhang, S.; Zhang, H.; Hertz, L.; Peng, L. Fluoxetine affects GluK2 editing, glutamate-evoked Ca(2+) influx and extracellular signal-regulated kinase phosphorylation in mouse astrocytes. J. Psychiatry Neurosci., 2011, 36, 322-338. http://dx. doi. org/ 10. 1503/jpn. 100094.
47. Lautens, L. L.; Chiou, X. G.; Sharp, J. D.; Young, W. S. 3rd.; Sprague, D. L.; Ross, L. S.; Felder, C. C. Cytosolic phospholipase A2 (cPLA2) distribution in murine brain and functional studies indicate that cPLA2 does not participate in muscarinic receptor-mediated signaling in neurons. Brain Res., 1998, 809, 18-30. http://dx. doi. org/10. 1016/s0006-8993(98)00806-3.
48. Balboa, M. A.; Balsinde., J. Involvement of calcium-independent phospholipase A2 in hydrogen peroxide-induced accumulation of free fatty acids in human U937 cells. J. Biol Chem., 2002, 27, 40384-40389. http://dx. doi. org/10. 1074/jbc. m206155200.
49. Sun, G. Y.; Xu, J.; Jensen, M. D.; Simonyi, A. Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J. Lipid Res., 2004, 45, 205-213. DOI: 10. 1194/jlr. R300016-JLR200.
50. Felder, C. C.; Kanterman, R. Y.; Ma, A. L.; Axelrod, J. Serotonin stimulates phospholipase A2 and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis. Proc. Natl. Acad. Sci. USA, 1990, 87, 2187-2191. http://dx. doi. org/10. 1073/ pnas. 87. 6. 2187.
51. Stout, B. D.; Clarke, W. P.; Berg, K. A. Rapid desensitization of the serotonin(2C) receptor system: effector pathway and agonist dependence. J. Pharmacol. Exp. Ther., 2002, 302, 957-962. http://dx. doi. org/10. 1124/jpet. 3023. 957.
52. Qu, Y.; Chang, L.; Klaff, J.; Seemann, R.; Rapoport, S. I. Imaging brain phospholipase A2-mediated signal transduction in response to acute fluoxetine administration in unanesthetized rats. Neuropsychopharmacology, 2003, 28, 1219-1226. http://dx. doi. org/ 10. 1038/sj. npp. 1300177.
53. Rapoport, S. I. Brain arachidonic and docosahexaenoic acid cascades are selectively altered by drugs, diet and disease. Prostaglandins Leuk. EssentFatty Acids, 2008, 79, 153-156. http://dx. doi. org/10. 1016/j. plefa. 2008. 09. 010.
54. Garcia, M. C.; Kim, H. Y. Mobilization of arachidonate and docosahexaenoate by stimulation of the 5-HT2A receptor in rat C6 glioma cells. Brain Res., 1997, 768, 43-48. http://dx. doi. org/ 10. 1016/s0006-8993(97)00583-0.
55. Yu, N.; Martin, J. L.; Stella, N.; Magistretti, P. J. Arachidonic acid stimulates glucose uptake in cerebral cortical astrocytes. Proc. Natl. Acad. Sci. U. S. A., 1993, 90, 4042-4046. http://dx. doi. org/ 10. 1073/pnas. 90. 9. 4042.
56. Allaman, I.; Fiumelli, H.; Magistretti, P. J.; Martin, J. L. Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology (Berl), 2011, 216, 75-84. http://dx. doi. org/10. 1007/s00213-011-2190-y.
57. Sorg, O.; Pellerin, L.; Stolz, M.; Beggah, S.; Magistretti, P. J. Adenosine triphosphate and arachidonic acid stimulate glycogenolysis in primary cultures of mouse cerebral cortical astrocytes. Neurosci. Lett., 1995, 188, 109-112. http://dx. doi. org/ 10. 1016/0304-3940(95)11410-x.
58. Hertz, L.; Xu, J.; Peng, L. Glycogenolysis and purinergic signaling glutamate and ATP at interface of metabolism and signaling in the brain. In: Advances of Neurobiology. Parpura, V., Schousboe, A., Verkhratsky, A. Eds.; Springer. 2014, in press.
59. Qu, Y.; Chang, L.; Klaff, J.; Seemann, R.; Greenstein, D.; Rapoport, S. I. Chronic fluoxetine upregulates arachidonic acid incorporation into the brain of unanesthetized rats. Eur. Neuro-psychopharmacol., 2006, 16, 561-571. http://dx. doi. org/10. 1016/ j. euroneuro. 2006. 01. 008.
60. Rao, J. S.; Ertley, R. N.; Lee, H. J.; Rapoport, S. I.; Bazinet, R. P. Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex. Pharmacogenom. J., 2006, 6, 413-420. http://dx. doi. org/10. 1038/ sj. tpj. 6500391.
61. Lee, H. J.; Rao, J. S.; Ertley, R. N.; Chang, L.; Rapoport, S. I.; Bazinet, R. P. Chronic fluoxetine increases cytosolic phospholipase A(2) activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat. Psychopharmacology (Berl), 2007, 190, 103-115. http://dx. doi. org/10. 1007/s00213-006-0582-1.
62. Little, J. T.; Ketter, T. A.; Kimbrell, T. A.; Danielson, A.; Benson, B.; Willis, M. W.; Post, R. M. Venlafaxine or bupropion responders but not nonresponders show baseline prefrontal and paralimbic hypometabolism compared with controls. Psychopharmacol. Bull, 1996, 32, 629-635. PubMed ID: 8993084.
63. Little, J. T.; Ketter, T. A.; Kimbrell, T. A.; Dunn, R. T.; Benson, B. E.; Willis, M. W.; Luckenbaugh, D. A.; Post, R. M. Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biol. Psychiatry, 2005, 57, 220-228. http://dx. doi. org/10. 1016/j. biopsych. 2004. 10. 033.
64. Videbech, P. PET measurements of brain glucose metabolism and blood flow in major depressive disorder: a critical review. Acta Psychiatr. Scand., 2000, 101, 11-20. http://dx. doi. org/10. 1034/ j. 1600-0447. 2000. 101001011. x.
65. Rasgon, N. L; Kenna, H. A; Geist, C.; Small, G.; Silverman, D. Cerebral metabolic patterns in untreated postmenopausal women with major depressive disorder. Psychiatry Res., 2008, 164, 77-80. http://dx. doi. org/10. 1016/j. pscychresns. 2007. 12. 006.
66. Kimbrell, T. A.; Ketter, T. A.; George, M. S.; Little, J. T.; Benson, B. E.; Willis, M. W.; Herscovitch, P.; Post, R. M. Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biol. Psychiatry, 2002, 51, 237-252. http://dx. doi. org/ 10. 1016/s0006-3223(01)01216-1.
67. Buchsbaum, M. S.; Wu, J.; Siegel, B. V.; Hackett, E.; Trenary, M.; Abel, L.; Reynolds, C. Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol. Psychiatry, 1997, 41, 15-22. http://dx. doi. org/10. 1016/s0006-3223(96)00097-2.
68. Mayberg, H. S.; Brannan, S. K.; Tekell, J. L.; Silva, J. A.; Mahurin, R. K.; McGinnis, S.; Jerabek, P. A. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol. Psychiatry, 2000, 48, 830-843. http://dx. doi. org/10. 1016/s0006-3223(00)01036-2.
69. Kennedy, S. H.; Evans, K. R.; Krüger, S.; Mayberg, H. S.; Meyer, J. H.; McCann, S.; Arifuzzman, A. I.; Houle, S.; Vaccarino, F. J. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am. J. Psychiatry, 2001, 158, 899-905. http://dx. doi. org/10. 1176/appi. ajp. 158. 987. 899.
70. Sublette, M. E.; Milak, M. S.; Hibbeln, J. R.; Freed, P. J.; Oquendo, M. A.; Malone, K. M.; Parsey, R. V.; Mann, J. J. Plasma polyunsaturated fatty acids and regional cerebral glucose metabolism in major depression. Prostaglandins Leukot. Essent. Fatty. Acids, 2009, 80, 57-64. http://dx. doi. org/10. 1016Zj. plefa. 2008. 11. 004.
71. Hundal, Ø. Major depressive disorder viewed as a dysfunction in astroglial bio energetic s. Med. Hypotheses, 2007, 68, 370-377. http://dx. doi. org/10. 1016/j. mehy. 2006. 06. 050.
72. Hertz, L.; Song, D.; Li, B.; Yan, E.; Peng, L. Importance of 'inflammatory molecules', but not necessarily of inflammation, in the pathophysiology of bipolar disorder and in the mechanisms of action of anti-bipolar drugs. NPBR, 2013, 19, 174-179. http://dx. doi. org/10. 1016/j. npbr. 2013. 09. 004.
73. Tharumaratnam, D.; Bashford, S.; Khan, S. A. Indomethacin induced psychosis. Postgrad. Med. J., 2000, 76, 736-737. http://dx. doi. org/10. 1136/pmj. 76. 901. 736.
74. Clunie, M.; Crone, L. A.; Klassen, L.; Yip, R. Psychiatric side effects of indomethacin in parturients. Can. J. Anaesth., 2003, 50, 586-568. http://dx. doi. org/10. 1007/bf03018645.
75. Jiang, H. K.; Chang, D. M. Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: five case reports. Clin. Rheumatol., 1999, 18, 339-345. http://dx. doi. org/10. 1007/s100670050114.
76. Müller, N. Immunology of major depression. Neuroimmuno-modulation, 2014, 21, 123-130.
77. Pae, C. U.; Yu, H. S.; Kim, J. J.; Lee, C. U.; Lee, S. J.; Lee, K. U.; Jun, T. Y.; Paik, I. H.; Serretti, A.; Lee, C. BanI polymorphism of the cytosolic phospholipase A2 gene and mood disorders in the Korean population. Neuropsychobiology, 2004, 49, 185-188. http://dx. doi. org/10. 1159/000077364.
78. Su, K. P.; Huang, S. Y.; Peng, C. Y.; Lai, H. C.; Huang, C. L.; Chen, Y. C.; Aitchison, K. J.; Pariante, C. M. Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol. Psychiatry, 2010, 67, 550-557. http://dx. doi. org/10. 1016/ j. biopsych. 2009. 11. 005.
79. Hertz, L; Xu, J; Song, D; Du, T; Li, B; Yan, E; Peng, L. Astrocytic Glycogenolysis: Mechanisms and Functions. Metabolic Brain Dis., 2014, in press. DOI: 10. 1007/s11011-014-9536-1.
80. Verkhratsky, A.; Rodriguez, J. J.; Parpura, V. Calcium signalling in astroglia. Mol. Cell Endocrinol., 2012, 353, 45-56. http://dx. doi. org/10. 1016/j. mce. 2011. 08. 039.
81. Yan, E.; Li, B.; Gu, L.; Hertz, L.; Peng L. Mechanisms for L-channel-mediated increase in [Ca(2+)](i) and its reduction by anti-bipolar drugs in cultured astrocytes combined with its mRNA expression in freshly isolated cells support the importance of astrocytic L-channels. Cell Calcium, 2013, 54, 335-342. http://dx. doi. org/10. 1016/j. ceca. 2013. 08. 002.
82. 2+]i in astrocytes mimic those of acute inhibition of TRPC1 channel activity. Cell Calcium, 2011, 50, 42-53. http://dx. doi. org/ 10. 1016/j. ceca. 2011. 05. 001.
83. 2+]i. Cell Calcium, 2014, 55, 166-174. http://dx. doi. org/10. 1016/j. ceca. 2014. 01. 002.
84. Verkhratsky, A.; Parpura, V. Store-operated calcium entry in neuroglia. Neurosci. Bull, 2014, 30, 125-133. http://dx. doi. org/ 10. 1007/s12264-013-1343-x.
85. Harteneck, C.; Plant, T. D.; Schultz, G. From worm to man: three subfamilies of TRP channels. Trends Neurosci., 2000, 23, 159-166. http://dx. doi. org/10. 1016/s0166-2236(99)01532-5.
86. Verkhratsky, A.; Reyes, R. C.; Parpura, V. TRP Channels Coordinate Ion Signalling in Astroglia. Rev. Physiol. Biochem. Pharmacol., 2014, 166, 1-22. doi: 10. 1007/112_2013_15.
87. 2+ dynamics and consequent glutamate release from rat astrocytes. Glia, 2008, 56, 821-835. http://dx. doi. org/10. 1002/glia. 20656.
88. 2+-dependent glycogen hydrolysis in mouse cerebral cortex. J. Neurosci., 1988, 8, 1922-1928. PubMed ID: 3385482.
89. + homeostasis and glycogen usage in brain. Neurochem. Res., 2013, 38, 472-485. http://dx. doi. org/10. 1007/s11064-012-0938-3.
90. Dougherty, U.; Sehdev, A.; Cerda, S.; Mustafi, R.; Little, N.; Yuan, W.; Jagadeeswaran, S.; Chumsangsri, A.; Delgado, J.; Tretiakova, M.; Joseph, L.; Hart, J.; Cohen, E. E.; Aluri, L.; Fichera, A.; Bissonnette, M. Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clin. Cancer Res., 2008, 14, 2253-2262. http://dx. doi. org/10. 1158/1078-0432. ccr-07- 4926.
91. Sanacora, G.; Treccani, G.; Popoli, M. Towards a glutamate hypothesis of depression An emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology, 2012, 62, 63-77. http://dx. doi. org/10. 1016/j. neuropharm. 2011. 07. 036.
92. Peng, L.; Li, B.; Du, T.; Wang, F.; Hertz, L. Does conventional anti-bipolar and antidepressant drug therapy reduce NMDA-mediated neuronal excitation by downregulating astrocytic GluK2 function? Pharmacol. Biochem. Behav., 2012, 100, 712-725. http://dx. doi. org/10. 1016/j. pbb. 2011. 03. 021.
93. Hertz, L., Zielke, H. R. Astrocytic control of glutamatergic activity: astrocytes as stars of the show. Trends Neurosci., 2004, 27, 735-743. http://dx. doi. org/10. 1016/j. tins. 2004. 10. 008.
94. Schousboe, A.; Bak, L. K.; Waagepetersen, H. S. Astrocytic Control of Biosynthesis and Turnover of the Neurotransmitters Glutamate and GAB A. Front. Endocrinol (Lausanne), 2013, 4, 102. DOI: 10. 3389/fendo. 2013. 00102.
95. Sanacora, G.; Banasr, M. From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol Psychiatry, 2013, 73, 1172-1179. http://dx. doi. org/10. 1016/j. biopsych. 2013. 03. 032.
96. Niciu. M. J.; Henter, I. D.; Sanacora, G.; Zarate, C. A Jr. Glial abnormalities in substance use disorders and depression: Does shared glutamatergic dysfunction contribute to comorbidity? World J. Biol. Psychiatry, 2014, 15, 2-16. http://dx. doi. org/10. 3109/ 15622975. 2013. 829585.
97. Lapidus, K. A.; Soleimani, L.; Murrough, J. W. Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr. Dis. Treat., 2013, 9, 1101-1112. DOI: 10. 2147/NDT. S36689.
98. Murrough, J. W.; Perez, A. M.; Pillemer, S.; Stern, J.; Parides, M. K.; aan, het, Rot, M.; Collins, K. A.; Mathew, S. J.; Charney, D. S.; Iosifescu, D. V. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol. Psychiatry, 2013, 74, 250-256. http://dx. doi. org/10. 1016/ j. biopsych. 2012. 06. 022.
99. Melyan, Z.; Lancaster, B.; Wheal, H. V. Metabotropic regulation of intrinsic excitability by synaptic activation of kainate receptors. J. Neurosci., 2004, 24, 4530-4534. http://dx. doi. org/10. 1523/ jneurosci. 5356-03. 2004.
100. Barbon, A.; Popoli, M.; La Via, L.; Moraschi, S.; Vallini, I.; Tardito, D.; Tiraboschi, E.; Musazzi, L.; Giambelli, R.; Gennarelli, M.; Racagni, G.; Barlati, S. Regulation of editing and expression of glutamate alpha-amino-propionic-acid (AMPA)/kainate receptors by antidepressant drugs. Biol. Psychiatry, 2006, 59, 713-720. http://dx. doi. org/10. 1016/j. biopsych. 2005. 10. 018.
101. 2+ permeability of unedited and edited versions of the kainate selective glutamate receptor GluR6. Proc. Natl. Acad. Sci. U. S. A., 1993, 90, 755-759. http://dx. doi. org/10. 1073/pnas. 90. 2. 755.
102. Barbon, A.; Gervasoni, A.; LaVia, L.; Orlandi, C.; Jaskolski, F.; Perrais, D.; Barlati, S. Human GluR6c, a functional splicing variants of GluR6, is mainly expressed in non-nervous cells. Neurosci. Lett., 2008, 434, 77-82. http://dx. doi. org/10. 1016/j. neulet. 2008. 01. 049.
103. Shaltiel, G.; Maeng, S.; Malkesman, O.; Pearson, B.; Schloesser, R. J.; Tragon, T.; Rogawski, M.; Gasior, M.; Luckenbaugh, D.; Chen, G.; Manji, H. K. Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol. Psychiatry, 2008, 13, 858-872. http://dx. doi. org/10. 1038/mp. 2008. 20.
104. Delorme, R.; Krebs, M. O.; Chabane, N.; Roy, I.; Millet, B.; Mouren-Simeoni, M. C.; Maier, W.; Bourgeron, T.; Leboyer, M. Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive compulsive disorder. Neuroreport, 2004, 15, 699-702. http://dx. doi. org/10. 1097/00001756-200403220-00025.
105. Sampaio, A. S.; Fagerness, J.; Crane, J.; Leboyer, M.; Delorme, R.; Pauls, D. L.; Stewart, S. E. Association between polymorphisms in GRIK2 gene and obsessive-compulsive disorder: a family-based study. CNS Neurosci. Ther., 2011, 17, 141-147. DOI: 10. 1111/j. 1755-5949. 2009. 00130. x.
106. Vialou, V.; Robison, A. J.; Laplant, Q. C.; Covington, H. E. 3rd.; Dietz, D. M.; Ohnishi, Y. N.; Mouzon, E.; Rush, A. J. 3rd.; Watts, E. L.; Wallace, D. L.; Iñiguez, S. D.; Ohnishi, Y. H.; Steiner, M. A.; Warren, B. L.; Krishnan, V.; Bolaños, C. A.; Neve, R. L.; Ghose, S.; Berton, O.; Tamminga, C. A.; Nestler, E. J. DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses. Nat. Neurosci., 2010, 13, 745-752. http://dx. doi. org/ 10. 1038/nn. 2551.
107. Cahoy, J. D.; Emery, B.; Kaushal, A.; Foo, L. C.; Zamanian, J. L.; Christopherson, K. S.; Xing, Y.; Lubischer, J. L.; Krieg, P. A.; Krupenko, S. A.; Thompson, W. J.; Barres, B. A. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J. Neurosci., 2008, 28, 264-278. http://dx. doi. org/10. 1523/jneurosci. 4178-07. 2008.
108. Lobo, M. K.; Zaman, S.; Damez-Werno, D. M.; Koo, J. W.; Bagot, R. C.; DiNieri, J. A.; Nugent, A.; Finkel, E.; Chaudhury, D.; Chandra, R.; Riberio, E.; Rabkin, J.; Mouzon, E.; Cachope, R.; Cheer, J. F.; Han, M. H.; Dietz, D. M.; Self, D. W.; Hurd, Y. L.; Vialou, V.; Nestler, E. J. ΔFosB induction in striatal medium spiny neuron subtypes in response to chronic pharmacological, emotional, and optogenetic stimuli. J. Neurosci., 2013, 33, 18381-18395. http://dx. doi. org/10. 1523/jneurosci. 1875-13. 2013.
109. Warren, B. L.; Vialou, V. F.; Iñiguez, S. D.; Alcantara, L. F.; Wright, K. N.; Feng, J.; Kennedy, P. J.; Laplant, Q.; Shen, L.; Nestler, E. J.; Bolaños-Guzmán, C. A. Neurobio logical sequelae of witnessing stressful events in adult mice. Biol. Psychiatry. 2013, 73, 7-14. http://dx. doi. org/10. 1016/j. biopsych. 2012. 06. 006.
110. Vollmayr, B.; Mahlstedt, M. M.; Henn, F. A. Neurogenesis and depression: what animal models tell us about the link. Eur. Arch. Psychiatry Clin. Neurosci., 2007, 257, 300-303. http://dx. doi. org/10. 1007/s00406-007-0734-2.
111. Pinna, G., Rasmusson, A. M. Up-regulation of neurosteroid biosynthesis as a pharmacological strategy to improve behavioural deficits in a putative mouse model of post-traumatic stress disorder. J. Neuroendocrinol, 2012, 24, 102-116. http://dx. doi. org/10. 1111/ j. 1365-2826. 2011. 02234. x.
112. Reid, T. E.; Kumar, K.; Wang, X. S. Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease. Curr. Top Med. Chem., 2013, 13, 1353-1362. http://dx. doi. org/10. 2174/15680266113139990039.
113. Rothman, R. B.; Baumann, M. H.; Savage, J. E.; Rauser, L.; McBride, A.; Hufeisen, S. J.; Roth, B. L. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation, 2000, 102, 2836-2841. http://dx. doi. org/10. 1161/01. cir. 102. 23. 2836.
114. Bai, C. F.; Liu, J. C.; Zhao, R.; Cao, W.; Liu, S. B.; Zhang, X. N.; Guo, H. J.; Yang, Q.; Yi, D. H.; Zhao, M. G. Role of 5-HT2B receptors in cardiomyocyte apoptosis in noradrenaline-induced cardiomyopathy in rats. Clin. Exp. Pharmacol. Physiol, 2010, 37, e145-e151. DOI: 10. 1111/j. 1440-1681. 2010. 05388. x.
115. Banes, A. K; Watts, S. W. Arterial expression of 5-HT2B and 5-HT1B receptors during development of DOCA-salt hypertension. BMC Pharmacol, 2003, 3, 12. http://dx. doi. org/10. 1186/1471-2210-3-12.
116. Rieckmann, N.; Kronish, I. M.; Shapiro, P. A.; Whang, W.; Davidson, K. W. Serotonin reuptake inhibitor use, depression, and long-term outcomes after an acute coronary syndrome: a prospective cohort study. JAMA Intern. Med., 2013, 173, 1150-1151. DOI: 10. 1001/jamainternmed. 2013. 910.
117. Ellfolk, M.; Malm, H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod. Toxicol, 2010, 30, 249-260. http://dx. doi. org/10. 1016/ j. reprotox. 2010. 04. 015.